Loop-Mediated Isothermal Amplification Discriminates Yaws Bacterium
|
By LabMedica International staff writers Posted on 05 Feb 2020 |
|
Image: The innuPREP MP Basic Kit A for fast, efficient isolation of DNA and RNA of either viral or bacterial origin (Photo courtesy of Analytik Jena).
Yaws, a neglected tropical disease caused by the bacterium Treponema pallidum subspecies pertenue, predominantly affects children living in low-income, rural communities of warm and humid regions.
Clinical manifestations of Yaws include lesions of the skin, bone, and cartilage, progressing to severe destructive lesions if left untreated. Serologic tests, including the T. pallidum particle agglutination and rapid plasma reagin tests remain the primary diagnostic tools for yaws. Newer point-of-care serologic tests have replaced traditional laboratory-based serologic assays in many settings
An international team of scientists working with the University of Freiburg (Freiburg, Germany) developed a novel molecular test to simultaneously detect T. pallidum and Haemophilus ducreyi based on mediator displacement Loop-Mediated Isothermal Amplification (LAMP). They validated the T. pallidum and H. ducreyi LAMP (TPHD-LAMP) by testing 293 clinical samples from patients with yaws-like lesions.
Swabs were collected from persons with yaws-like ulcers and placed in AssayAssure Multilock (Sierra Molecular, Princeton, NJ, USA) transport medium, then frozen at −20 °C until transported to Mast Diagnostica GmbH laboratory (Reinfeld, Germany). DNA was extracted from the samples by using innuPREP MP Basic Kit A (Analytik Jena, Jena, Germany). Isolated DNA was kept frozen at −20 °C until it was used for biplex T. pallidum and H. ducreyi LAMP (TPHD-LAMP), singleplex T. pallidum and H. ducreyi LAMP assays, and quantitative polymerase chain reaction (qPCR) testing.
The team detected T. pallidum in 59 (20.1%) samples, H. ducreyi in 155 (52.9%) samples, and T. pallidum and H. ducreyi co-infection in 19 (6.5%) samples using qPCR. When tested by TPHD-LAMP, they detected T. pallidum in 60 (20.5%) samples and H. ducreyi in 163 (55.6%) samples. They detected both targets in 12 (4.1%) samples. Taking qPCR as the reference standard, the diagnostic sensitivity of the TPHD-LAMP assay for T. pallidum was 84.7% and the specificity was 95.7%. For H. ducreyi, the sensitivity of the TPHD-LAMP assay was 91.6% and the specificity was 84.8%.
The authors concluded that their novel assay provided rapid molecular confirmation of T. pallidum and H. ducreyi DNA and might be suitable for use at the point of care. TPHD-LAMP could support yaws eradication by improving access to molecular diagnostic tests at the district hospital level. The study was published in the February 2020 issue of the journal Emerging Infectious Diseases.
Related Links:
University of Freiburg
Sierra Molecular
Mast Diagnostica
Analytik Jena
Clinical manifestations of Yaws include lesions of the skin, bone, and cartilage, progressing to severe destructive lesions if left untreated. Serologic tests, including the T. pallidum particle agglutination and rapid plasma reagin tests remain the primary diagnostic tools for yaws. Newer point-of-care serologic tests have replaced traditional laboratory-based serologic assays in many settings
An international team of scientists working with the University of Freiburg (Freiburg, Germany) developed a novel molecular test to simultaneously detect T. pallidum and Haemophilus ducreyi based on mediator displacement Loop-Mediated Isothermal Amplification (LAMP). They validated the T. pallidum and H. ducreyi LAMP (TPHD-LAMP) by testing 293 clinical samples from patients with yaws-like lesions.
Swabs were collected from persons with yaws-like ulcers and placed in AssayAssure Multilock (Sierra Molecular, Princeton, NJ, USA) transport medium, then frozen at −20 °C until transported to Mast Diagnostica GmbH laboratory (Reinfeld, Germany). DNA was extracted from the samples by using innuPREP MP Basic Kit A (Analytik Jena, Jena, Germany). Isolated DNA was kept frozen at −20 °C until it was used for biplex T. pallidum and H. ducreyi LAMP (TPHD-LAMP), singleplex T. pallidum and H. ducreyi LAMP assays, and quantitative polymerase chain reaction (qPCR) testing.
The team detected T. pallidum in 59 (20.1%) samples, H. ducreyi in 155 (52.9%) samples, and T. pallidum and H. ducreyi co-infection in 19 (6.5%) samples using qPCR. When tested by TPHD-LAMP, they detected T. pallidum in 60 (20.5%) samples and H. ducreyi in 163 (55.6%) samples. They detected both targets in 12 (4.1%) samples. Taking qPCR as the reference standard, the diagnostic sensitivity of the TPHD-LAMP assay for T. pallidum was 84.7% and the specificity was 95.7%. For H. ducreyi, the sensitivity of the TPHD-LAMP assay was 91.6% and the specificity was 84.8%.
The authors concluded that their novel assay provided rapid molecular confirmation of T. pallidum and H. ducreyi DNA and might be suitable for use at the point of care. TPHD-LAMP could support yaws eradication by improving access to molecular diagnostic tests at the district hospital level. The study was published in the February 2020 issue of the journal Emerging Infectious Diseases.
Related Links:
University of Freiburg
Sierra Molecular
Mast Diagnostica
Analytik Jena
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Gel Cards
DG Gel Cards
Sample Transportation System
Tempus1800 Necto
Latest Microbiology News
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Hematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more